Search results

  1. V.R.T.

    Preprint Mechanisms of sex differences in acute and long COVID sequelae in mice, 2025, Liu et al.

    This would seem to be more evidence against viral persistance driving symptoms then. If only we could get the US LC research lot to listen... But were these found during autopsies of the mice and/or in tissues that can't safely be tested in live humans?
  2. V.R.T.

    Do you have small fiber neuropathy (SFN)?

    I have many symptoms of SFN but have never had a biopsy
  3. V.R.T.

    United Kingdom: Action for ME's PRIME project - research infrastructure

    I also appreciated the way he framed it as 'we need to accelerate ME research towards effective treatments and diagnostics'. I think so much emphasis is often put by researchers on biomarkers and tests that you question whether they understand what the real priority is. Whereas when they...
  4. V.R.T.

    United Kingdom: Action for ME's PRIME project - research infrastructure

    Iirc Chris also said they would meet once a week? It sounds like exactly what ME research in this country needs. Some unity and direction. I'm particularly excited by the possibility of new specialists in DecodeME gene areas getting involved.
  5. V.R.T.

    Who will pursue treatments for low NK cell patients?

    Sounds like if it's CD38 inhibition rather than plasma cell depletion we want this drug might be more effective than daratumumab?
  6. V.R.T.

    Who will pursue treatments for low NK cell patients?

    Interesting! If this is the case then the Scheibenbogen trial will be worth keeping an eye on if it goes ahead. I hope they measure NK cells before treatment too.
  7. V.R.T.

    Preprint Initial findings from the DecodeME genome-wide association study of myalgic encephalomyelitis/chronic fatigue syndrome, 2025, DecodeMe Collaboration

    Besides SequenceME, is it possible/practical for someone to do a study focussing on all or some of these genes? My understanding is that you don't need anywhere near as many participants for statistical significance when you are looking at a specific gene rather than at the genome as a whole. It...
  8. V.R.T.

    Trial Report Plasma cell targeting with the anti-CD38 antibody daratumumab in ME/CFS -a clinical pilot study, 2025, Fluge et al

    Isnt that the one thats in Polar Bear livers thats toxic to humans? Answered my own question - yes, in high quantities. https://en.wikipedia.org/wiki/Hypervitaminosis_A
  9. V.R.T.

    Who will pursue treatments for low NK cell patients?

    Does the anti CD38 drug Scheibenbogen is using also require NK cells to work? Do you have any speculations about what sort of approach the other subgroup might need in this scenario?
  10. V.R.T.

    Who will pursue treatments for low NK cell patients?

    I assume this stuff will be investigated after dara p2 if it succeeds but that is a way off. Personally I wish they could have gone straight to a larger phase 3 with mostly high nk cell patients but subgroups of artificially raised and low NK cell patients. If there trial is postive and it was...
  11. V.R.T.

    Development and validation of blood-based diagnostic biomarkers for [ME/CFS] using EpiSwitch®… 2025, Hunter et al. (Oxford Biodynamics)

    Every time someone does this it plays into BPS hands! Can't researchers understand that by constantly announcing they have found a biomarker based on premature and in this case poorly conducted findings it delegitamises them AND us in the eyes of the medical establishment.
  12. V.R.T.

    Efgartigimod (Vyvgart) - what could the trial data possibly tell us?

    If they truly believe the drug helped them, and the drug company are refusing to release the data, what else can they do but call for another trial?
  13. V.R.T.

    Efgartigimod (Vyvgart) - what could the trial data possibly tell us?

    Fwiw a reddit comment about the study questionnaires from a participant. I'm not saying this drug definitely worked but I think there are a lot of elements of this trial fiasco that fit with what we have talked about in terms of problematic trial design. I think the NIH would do better to...
  14. V.R.T.

    Trial Report Plasma cell targeting with the anti-CD38 antibody daratumumab in ME/CFS -a clinical pilot study, 2025, Fluge et al

    https://thesicktimes.org/2025/10/10/vyvgart-brought-us-back-to-life-but-the-long-covid-trial-was-canceled-we-are-calling-on-the-nih-and-hhs-to-study-the-drug/ Article about these trial participants.
  15. V.R.T.

    Efgartigimod (Vyvgart) - what could the trial data possibly tell us?

    https://thesicktimes.org/2025/10/10/vyvgart-brought-us-back-to-life-but-the-long-covid-trial-was-canceled-we-are-calling-on-the-nih-and-hhs-to-study-the-drug/ Don't know if this is the right place but if all of these people who say they improved and are asking for another trial definitely got...
  16. V.R.T.

    Keystone symposium Long COVID and Other Post-Acute Infection Syndromes August 10-13 2025

    Did he present any interesting data or was it just about the study structure etc? These studies have taken their time, thats for sure.
  17. V.R.T.

    Preprint Initial findings from the DecodeME genome-wide association study of myalgic encephalomyelitis/chronic fatigue syndrome, 2025, DecodeMe Collaboration

    Is it possible people with depression are more prone to ME? Or that a percentage of depression cases are actually people with the prodromal form of ME, whether or not it ever turns into the real thing?
  18. V.R.T.

    Keystone symposium Long COVID and Other Post-Acute Infection Syndromes August 10-13 2025

    Does anyone know what happened to Altmann's WILCO study? It would be great if he could join us on here some time.
  19. V.R.T.

    Development and validation of blood-based diagnostic biomarkers for [ME/CFS] using EpiSwitch®… 2025, Hunter et al. (Oxford Biodynamics)

    I mean apart from the fact that if it was real it would be life changing for every single one of us. I understand your skepticism and I share it, but I think you go a little far here.
  20. V.R.T.

    Development and validation of blood-based diagnostic biomarkers for [ME/CFS] using EpiSwitch®… 2025, Hunter et al. (Oxford Biodynamics)

    How long would a good quality independent replication take and what would it look like?
Back
Top Bottom